ContraVir

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch ContraVir and buy or sell other stocks, ETFs, and their options commission-free!

About CTRV

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate, Rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. 

CEO
Kaouthar Lbiati, MD
CEOKaouthar Lbiati, MD
Employees
Employees
Headquarters
Morristown, New Jersey
HeadquartersMorristown, New Jersey
Founded
2013
Founded2013
Employees
Employees

CTRV Key Statistics

Market cap
604.30K
Market cap604.30K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
12.10K
Average volume12.10K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$4.98
52 Week high$4.98
52 Week low
$0.033
52 Week low$0.033

Stock Snapshot

The current ContraVir(CTRV) stock price is $3.33, with a market capitalization of 604.3K.

ContraVir(CTRV) stock opened on 2026-03-10 at —. The price climbed to — and dipped to —.

ContraVir(CTRV) shares are trading with a volume of 0, against a daily average of 12.1K.

In the last year, ContraVir(CTRV) shares hit a 52-week high of $4.98 and a 52-week low of $0.03.

In the last year, ContraVir(CTRV) shares hit a 52-week high of $4.98 and a 52-week low of $0.03.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.